340B Needs A Stronger Fix Than Dispute Resolution Rule, Provider Lawsuit Against HHS Argues
Drug manufacturer actions against contract pharmacies require immediate attention, provider suit says, though HHS’ 340B dispute resolution process ‘holds promise.’
You may also be interested in...
340B Fight: Lilly ‘Disagrees’ With HHS Advisory Stating Discounts To Contract Pharmacies Are Required
Lilly will not change its 340B discount restrictions in light of the advisory, which was released after HHS was sued by hospitals and other groups seeking a regulatory response against pharma actions.
President-elect Biden’s Administration may be less convinced than Trump’s about the need to make changes in the way providers benefit from the outpatient drug discount program.
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.